BAH stock jumped on better-than-expected $1.81 EPS despite declining revenue of $11.09 billion in Q1. Booz Allen Hamilton shares climbed 10.1% to $72.53 after reporting first-quarter earnings of $1.81 per share, surpassing estimates of $1.49. The gain contrasted with minim
Higher global vehicle sales and strong electrified vehicle demand offset US import tariffs and increased incentives for the automaker. Kia Corporation posted a 2.3% year-on-year increase in second-quarter net profit to KRW 2,327.8 trillion ($1.59 billion), driven by record
Boston Beer’s Q2 EPS of $4.96 exceeded estimates, driven by 60 basis points of margin expansion and a $1.31 litigation benefit. Boston Beer reported second-quarter GAAP diluted EPS of $4.96, beating Wall Street estimates of $4.83, while non-GAAP EPS reached $3.65. The beat
Swedish private equity firm EQT increases its bid for Perpetual to A$2.6bn, valuing shares at A$22.50, up 2% from its prior proposal. EQT AB has raised its takeover bid for Australian investment manager Perpetual to approximately A$2.6bn ($1.8bn), valuing the company at A$
Global equities rise after Iran halts attacks, sending Brent crude down 6.3% to $90.70 ahead of key central bank meetings this week. Global stock markets advanced Monday as a pause in Middle East hostilities drove oil prices sharply lower, easing inflation concerns. Brent
VBX agrees to supply 2-3 million tonnes of bauxite annually to a Chinese group under a framework deal for Wuudagu project development. VBX has signed a bauxite offtake and investment framework agreement with a Hong Kong-based unit of a Chinese aluminium group. The deal out
Argenx buys Forte Biosciences for $77 per share Argenx SE is acquiring Forte Biosciences for $77 per share in cash, valuing the deal at $2.2B. The acquisition adds Forte's lead program to argenx's portfolio. The deal expands argenx's immunology offerings wi
AstraZeneca announces a $1.06 per share interim dividend and plans to raise annual payouts to $3.30 by 2026. AstraZeneca PLC (AZN) declared a $1.06 per share interim dividend, payable on September 8 to shareholders of record as of August 7. The ex-dividend date is also set
AZN core EPS of $2.63 surpasses expectations by $1.36 as oncology sales fuel revenue growth of 5% year over year. AstraZeneca posted second-quarter core earnings per share of $2.63, beating Wall Street estimates by $1.36. The outperformance was driven by robust sales of it
Nvidia, Microsoft, and Meta lead a coalition urging Washington to support open-weight AI models to counter concentration risks and foster innovation. Nvidia, Microsoft, Meta, IBM, and venture firm Andreessen Horowitz signed an open letter urging the U.S. government to supp
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.